Effect of hyperthyroidism and its treatment on bone mineral content.

Patients with hyperthyroidism may develop osteopenia associated with fractures; however, there has been no general agreement on the incidence of osteopenia in hyperthyroidism or the recovery of the mineral loss after treatment of hyperthyroidism. We conducted a longitudinal prospective study on the effect of hyperthyroidism and its treatment on bone mineral content (BMC) using photon absorptiometry. We observed that both young and older hyperthyroid patients showed a significantly decreased baseline BMC compared with age- and sex-matched controls. We also observed a slight recovery of BMC in hyperthyroid patients at the two-year interval after a euthyroid state had been achieved. However, the BMC was still much lower than that of controls, and we did not find any significant restoration of BMC following "cure" of hyperthyroidism.

Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study.

Several studies have reported that short-term thyroid replacement to the euthyroid state in hypothyroid patients produces loss of both cortical and trabecular bone. However, long-term follow-up studies on this subject have not been reported. We conducted a 3 year follow-up study on 35 white male patients, including 24 patients (group 1 and 2) with hypothyroidism receiving thyroid hormone replacement to the euthyroid state and 11 patients (groups 3 and 4) with Graves' disease. The bone mineral content of the distal radius was determined by single-photon absorption techniques with an iodine 125 source. It was found that there was no statistically significant difference in bone mineral content by year for any group, indicating no evidence of significant loss of cortical bone mineral by thyroid hormone replacement to the euthyroid state in hypothyroid patients.

Effect of calcitonin treatment on the natural course of bone demineralization in Paget's disease.

Numerous studies have been done to determine the effects of long term calcitonin (CT) treatment on Paget's disease of bone, but very few studies have been undertaken to determine the long term CT effect on nonpagetic bone in man. Because of conflicting results of the CT effect on osteoporosis and also for further understanding of the role of CT on normal bone, we conducted a longitudinal prospective study on the effect of CT treatment on nonpagetic bone in patients with Paget's disease using monoenergetic photon absorptionmetry method. Patients with Paget's disease were given salmon CT daily for a period of 3 yr, the bone mineral content (BMC) in the nonpagetic distal radius was measured periodically for 3 yr, and the data were compared with those of the control group of patients with Paget's disease not receiving CT treatment. It was found that the control group showed a persistent gradual decrease in BMC during the study period of 3 yr, but the CT-treated group showed no decrease in BMC during the 3-yr period of treatment. Our study suggests that CT treatment may delay the natural course of bone demineralization with aging in patients with Paget's disease.

Chest pain as a presentation of reactive hypoglycemia.

Reported herein is a patient with multiple hospital admissions for atypical chest pain syndrome who underwent extensive noninvasive and invasive cardiologic testing to exclude ischemic heart disease as an etiology. During one episode of chest pain, the patient was found to have hypoglycemia with a blood sugar level of 46 ml/dl. Two subsequent oral glucose tolerance tests reproduced chest pain during hypoglycemia with values of 47 ml/dl and 27 ml/dl. The patient had previously had no significant clinical response to typical antianginal medications. Following evidence of concurrent hypoglycemia, the chest pain syndrome has significantly decreased with the patient on a low carbohydrate diet.

Noninvasive assessment of vascular disease in the lower limbs of diabetics.

One hundred and fifty seven limbs of diabetic patients free of any symptoms or signs of arterial insufficiency, were studied using noninvasive techniques to determine vascular distensibility in the lower extremities. A relationship between these values and the classification of the diabetic in terms of age, duration of diabetes and control of diabetes was sought. The results revealed a distinct inverse relationship between vascular distensibility and age of the diabetic subject, analogous to the trend found in a normal, non-diabetic group of volunteers. Furthermore, comparison of distensibility in normal and diabetic subjects within the same age group showed lowered values among the diabetics. However, the study revealed little or no apparent relationship to either duration or control of diabetes.

Diarylheptanoids from the leaves of Alnus hirsuta Turcz.

Diarylheptanoids, (5S)-1,7-bis-(3,4-dihydroxyphenyl)-5-hydroxyheptane-3-one (1, hirsutanonol), (5S)-1,7-bis-(3,4-dihydroxyphenyl)-heptane-3-one-5-O-beta-D-xylopyranosi de (2, oregonin), (5R)-1,7-bis-(3,4-dihydroxyphenyl)-heptane-5-O-beta-D-xylopyranoside (3), and (5R)-1,7-bis-(3,4-dihydroxyphenyl)-heptane-5-O-beta-D-glucopyranoside (4) were isolated from the leaves of Alnus hirsuta Turcz. The structures of these compounds were identified based on the spectral and physicochemical data.

Antioxidative phenolic compounds from the roots of Rhodiola sachalinensis A. Bor.

The acetone extract of the roots of Rhodiola sachalinensis has furnished six phenolic compounds which exhibited significant scavenging effects against DPPH free radical. The structures of these compounds were identified and determined as gallic acid (1), (-)-epigallocatechin 3-O-gallate (2), kaempferol (3), kaempferol 7-O-alpha-L-rhamnopyranoside (4), herbacetin 7-O-alpha-L-rhamnopyranoside, (5) and rhodiolinin (6) by physico-chemical and spectral evidences.

Inhibition of cyclooxygenase-2 expression by diarylheptanoids from the bark of Alnus hirsuta var. sibirica.

Two known diarylheptanoids, oregonin (1), (5S)-1,7-bis-(3,4-dihydroxyphenyl)-heptane-3-one-5-O-beta-D-xylopyranosi de and hirsutanonol (2), (5S)-1,7-bis-(3,4-dihydroxyphenyl)-5-hydroxyheptane-3-one isolated from the bark of Alnus hirsuta var. sibirica, showed significant inhibitory effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cyclooxygenase-2 (COX-2) expression in immortalized human breast epithelial MCF10A cells.

Diarylheptanoids with in vitro inducible nitric oxide synthesis inhibitory activity from Alnus hirsuta.

Four diarylheptanoids were isolated from the leaf of Alnus hirsuta (Betulaceae) and have been assessed for nitric oxide (NO) production inhibitory effects in vitro. Oregonin (1) and hirsutanonol (2) were found to be potent inducible nitric oxide synthase (iNOS) inhibitors. Compounds 1 and 2 showed inhibition of NO synthesis in dose-dependent manners by murine macrophage-like RAW 264.7 cells stimulated with interferon-gamma (IFN-gamma) plus lipopolysaccharide (LPS). Their 50% inhibitory concentrations (IC50) were 3.8 and 14.3 microM, respectively. The inhibitory effects of these compounds on NO synthesis were due to suppression of iNOS mRNA expression as determined by Northern blotting.